Alfons0_7252_
Bronze
- Joined
- Nov 5, 2025
- Posts
- 412
- Reputation
- 232
Volufiline became popular because in vitro studies suggested it could enhance the activation of PPAR gamma (Peroxisome Proliferator-Activated Receptor gamma), a nuclear receptor that acts as a key regulator of adipogenesis—the process by which new fat cells are formed. Activation of PPAR gamma occurs when a ligand binds to it, triggering gene expression that promotes the differentiation and lipid storage of adipocytes.
These studies indicated that Volufiline increased the sensitivity of PPAR gamma to activation by around 535%, rather than activating it directly.
However, these findings are not directly applicable to humans, since we are not simply isolated cells in a controlled environment. For Volufiline to be effective in real conditions, it would need to penetrate the epidermis and reach the target tissue, which makes its effectiveness highly questionable.
Rosiglitazone, the alternative I’m referring to, directly activates (agonizes) PPAR gamma, meaning it binds to the receptor and triggers its activity without relying on increased sensitivity. This is a much more direct and pharmacologically robust mechanism. Unlike Volufiline, Rosiglitazone has been extensively studied in vivo, including in animal models and humans, providing a stronger evidence base for its effects.
In mouse studies—which are biologically closer to humans—Rosiglitazone has been shown to significantly increase adipose tissue through enhanced adipocyte differentiation and lipid storage. Beyond that, it has also demonstrated consistent effects on improving insulin sensitivity and regulating glucose metabolism, which are well-documented outcomes of PPAR gamma activation.
Topical:
Injected subq
pubmed.ncbi.nlm.nih.gov
These studies indicated that Volufiline increased the sensitivity of PPAR gamma to activation by around 535%, rather than activating it directly.
However, these findings are not directly applicable to humans, since we are not simply isolated cells in a controlled environment. For Volufiline to be effective in real conditions, it would need to penetrate the epidermis and reach the target tissue, which makes its effectiveness highly questionable.
Rosiglitazone, the alternative I’m referring to, directly activates (agonizes) PPAR gamma, meaning it binds to the receptor and triggers its activity without relying on increased sensitivity. This is a much more direct and pharmacologically robust mechanism. Unlike Volufiline, Rosiglitazone has been extensively studied in vivo, including in animal models and humans, providing a stronger evidence base for its effects.
In mouse studies—which are biologically closer to humans—Rosiglitazone has been shown to significantly increase adipose tissue through enhanced adipocyte differentiation and lipid storage. Beyond that, it has also demonstrated consistent effects on improving insulin sensitivity and regulating glucose metabolism, which are well-documented outcomes of PPAR gamma activation.
Topical:
Injected subq
Impact of Rosiglitazone on Subdermal Adipose Tissue Growth and Lipid Droplet Formation: An In Vitro and In Vivo Study - PubMed
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
pubmed.ncbi.nlm.nih.gov
Last edited:
